38 results about "Microvesicle" patented technology

Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.

Disclosed herein are populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and / or prophylactic indications.

The present application relates to the technical field of platelet exosome separation, and discloses a platelet exosome multistage laminar flow separation device, which comprises a liquid storage tank, a sleeve frame is symmetrically sleeved outside the liquid storage tank, a laminar flow box for laminar flow is arranged below the liquid storage tank, a first separation cabin for realizing primary separation is arranged below the laminar flow box, a second separation cabin for realizing resonance separation is arranged below the first separation cabin, a shunt box for shunting is arranged below the second separation cabin, and a plurality of collection tubes are arranged below the shunt box in an array, the present application realizes stable rectification of a sample and sheath liquid through the laminar flow box, the inertial force and the Dean force are utilized to accurately grade microvesicles, exosomes and cell fragments in combination with the gradually deepening spiral groove structure of the conical core in the first separation cabin, and the second resonance separation is performed on the exosomes through the resonance screens with different amplitudes and phase differences arranged in the second separation cabin, so that the enrichment purity of the exosomes is significantly improved.

The invention relates to the technical field of medical materials, in particular to a composition for soft tissue increment and a preparation method thereof, and the composition for soft tissue increment comprises a plasma matrix compressed material and a microvesicle concentrated solution. The composition for soft tissue increment provided by the invention comprises a plasma matrix compressed material and a microvesicle concentrated solution, the plasma matrix compressed material is rich in effective substances such as platelets and immune cells, has a compact three-dimensional fibrous protein network structure, and can provide a required scaffold for soft tissue regeneration, so that the soft tissue regeneration effect is improved. The microvesicle concentrated solution contains a large number of effective biological components such as cell factors and signal molecules, regeneration of local soft tissue can be further regulated and controlled, the microvesicle concentrated solution and the microvesicle concentrated solution have a synergistic effect, the excellent soft tissue regeneration promoting capacity is achieved, a complete autologous source is achieved, connective tissue transplantation surgery is replaced, and the application prospect is wide. The excellent performance is shown in the clinical application of soft tissue regeneration.

Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.

The application belongs to the technical field of exosome processing, and discloses an exosome microvesicle nondestructive separation and purification device, which comprises a sealed separation box, a laminated assembly is arranged in the inner cavity of the sealed separation box, the laminated assembly is sleeved outside a central shaft assembly, a pressure plate is arranged at the top end of the laminated assembly, and a synchronous driving assembly is arranged. When in the compressed state, the micro-nano groove forms a precise nanoscale channel for interception and filtration, and when in the relaxed state, the elastic sheet rebounds rapidly with the release of the axial pressure, the cross-sectional geometry of the micro-nano groove is deformed, the periodic geometric deformation breaks the mechanical stability of the filter cake layer from the physical level, the particles originally stuck in the groove or adsorbed on the surface lose the clamping force instantaneously, and are automatically detached from the surface fluid under the shearing action of the surface fluid, so that the flux decay rate of the device is controlled at a small value under long-time operation, and continuous and stable filtration in the true sense is realized.

The invention discloses a stem cell-based microvesicle as well as a preparation method and application thereof, belongs to the technical field of biological tissue engineering, and particularly relates to a preparation method of the stem cell-based microvesicle, which comprises the following steps: culturing stem cells until the cell fusion degree is 80-90%, performing hypoxia treatment, and cleaning for 2-3 times; standing and culturing the cleaned stem cells, then adding a calcium ion carrier, and carrying out ultrasonic treatment; the serum-free basic culture medium containing the calcium ion carrier is immediately absorbed and removed, the cells are cleaned through PBS, culture is conducted for 24 h, and cell supernatant is collected and merged respectively; performing first centrifugation to remove cell debris; performing second centrifugation to remove dead cells and large cell debris; carrying out third centrifugation to remove organelles; fourth centrifugation is carried out, large vesicles are removed, and a final supernatant is obtained; and filtering and centrifuging to obtain a microvesicle precipitate. The preparation method of the microvesicles aims at systematically improving the yield and biological activity of the stem cell microvesicles through low-oxygen pre-stimulation, ultrasonic-calcium ion carrier synergistic induction and differential centrifugation.

The invention relates to the field of agricultural microbial technology and soil remediation, in particular to application of microvesicle bacteria and a microbial agent thereof in saline-alkali soil, the name of the microvesicle bacteria is Microbulbifer sp.PM1, the preservation unit is China Center for Type Culture Collection, the preservation acceptance date is January 4, 2026, and the preservation number is CGMCC NO: 37273. Through tests and determination, the microbial agent prepared from the PM1 has important application value in the field of saline-alkali soil improvement, especially in high-quality and yield-increasing cultivation of corn.

This application provides a biomimetic self-driven microvesicle, its preparation method, and its application, belonging to the field of nanobiodelivery technology. This application utilizes a triple synergistic mechanism of a hybrid biomimetic membrane, a magneto-electro-thermal responsive core, and a pH / H2S dual-response release. Driven by a gradient rotating magnetic field generator, the near-infrared photothermal modulation unit softens the cell membrane through thermal effects, and a focused femtosecond pulsed electric field module forms reversible ultrapores. This allows the biomimetic self-driven microvesicles to precisely pass through the reversible ultrapores, then migrate and accumulate deep within the target cell membrane, significantly improving transmembrane efficiency and reducing non-specific damage. This makes it suitable for high-end applications such as deep tumor treatment, blood-brain barrier penetration, and oral delivery of biological drugs.

The invention provides a microvesicle-loaded DC vaccine as well as a preparation method and application thereof, DC is taken as a carrier, microvesicles are loaded, and the DC-loaded microvesicles are derived from hepatoma carcinoma cells Hepa1-6; the preparation method comprises the following steps: (1) culturing liver cancer Hepa1-6 cells, exposing the cells in an ultraviolet environment for irradiation, then collecting cell supernatant, and extracting MPs; (2) obtaining bone marrow single cells, firstly inducing the bone marrow single cells into imDC (imDC), and then inducing the bone marrow single cells into mature DC (mDC); and (3) incubating the DC and the MPs to obtain the DC vaccine loaded by the microvesicles. The invention also discloses an application of the DC vaccine loaded by the microvesicles in preparation of drugs or preparations for treating liver cancer. The DC vaccine loaded by the microvesicles can promote the activation of CD8 + T cells and the killing ability to liver cancer cells. According to the present invention, the liver cancer cells can be specifically killed without damaging other tissues, the specific recognition and killing function of the T cells on the tumor cells can be enhanced, and the tumor immune escape can be easily overcome.

The present invention generally relates to the field of ultrasound contrast-agents (USCA). In particular, it relates to a freeze-dried composition comprising an amphiphilic material and a mixture of freeze-drying protecting components, which may be reconstituted for preparing a suspension of gas-filled microvesicles with calibrated size, useful in diagnostic or therapeutic applications. It further relates to the method for the preparation of such freeze-dried composition.

The present invention relates to the manufacture of a freeze-dried product for the preparation of a suspension of aerated microvesicles, and to a suspension of aerated microvesicles prepared by reconstitution of the freeze-dried precursor with a physiologically acceptable liquid carrier in the presence of a physiologically acceptable gas. According to the invention, a freeze-dried product is obtained by freeze-drying the emulsion formulation in batches.

This invention discloses the application of urinary microvesicle proteins as diagnostic markers for renal cell carcinoma. The protein markers derived from urinary extracellular vesicles associated with clear cell renal carcinoma are characterized by being selected from one or more of the following proteins: CSPG4, AQP1, PLIN2, CA9, and HAVCR1. The invention also describes the application of reagents for detecting these protein markers in the preparation of auxiliary diagnostic reagents for clear cell renal carcinoma. The inventors, using flow cytometry, analyzed 200 patients and found that five proteins derived from urinary extracellular vesicles could effectively distinguish patients with clear cell renal carcinoma from controls (including healthy individuals, patients with benign renal tumors, patients with benign renal cysts, and patients with chronic kidney disease).

The application relates to an anti-impact PE pipe and a preparation method thereof, and belongs to the technical field of polymer composite materials. The components of the PE pipe are as follows: calcium carbonate whiskers 6.2-9.5 wt%, an anti-impact modifier 4.4-5.8 wt%, a lubricant 0.2-0.3 wt%, an antioxidant 0.15-0.2 wt%, an ultraviolet absorber 0.11-0.14 wt% and color master granules 2.6-3.2 wt%, and the balance is polyethylene resin. The disulfide structure in the molecular chain of the anti-impact modifier is loaded between the calcium carbonate whiskers in the form of multi-point anchoring through chelation to form a reinforcing and impact energy dispersion network, meanwhile, the polycyclohexyl segment in the molecular chain forms a large number of "microvesicle" unit structures on the surface of the calcium carbonate whiskers, absorbs impact energy and uniformly disperses and transitions the impact energy through the slippage deformation of the vesicle structure, and the anti-impact performance of the PE pipe is effectively improved.

To provide stem cells and exosome compositions having therapeutic utility to treat a variety of diseases and disorders, e.g., cardiovascular disease, Duchenne muscular dystrophy, and fibrotic disease.SOLUTION: The invention provides an exosome or microvesicle selected from among an iPSC cell, an embryonic stem cell, and a stem cell that has been contacted with an effective amount of an isoxazole compound, a derivative or equivalent thereof, or Danazol, where the exosome or microvesicle overexpresses one or more of: a) a microRNA (miRNA) selected from among mir-373, mir-210, mir-377, mir-367, mir-520, mir-548ah, mir-335, mir-21, mir-30c, mir-214 and mir-548q; and / or b) one or more proteins selected from among Tsg101, CD9, Hsp70, Flotillin-1 and GAPDH.SELECTED DRAWING: None

Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.

Provided is a method for promoting generation of a mitochondria-containing microvesicle and a treating method thereof. Specifically, provided is a method for promoting generation of the mitochondria-containing microvesicle with a combination of a mitochondrial generation promoting factor and an extracellular vesicle generation promoting factor. Also provided is a method for generating an extracellular vesicle composition, comprising: co-culturing cells having mitochondria with the mitochondrial generation promoting factor and the extracellular vesicle generation promoting factor to obtain the extracellular vesicle composition rich in the mitochondria-containing microvesicle. Adding the above factors may promote the cells to generate the mitochondria-containing microvesicle. The collected mitochondria are encapsulated by the microvesicle, and therefore can be easily stored and transferred into the cells. Also provided are an isolated extracellular vesicle composition, a pharmaceutical composition comprising the same, and a method for treating diabetes and / or renal injury by administering a medicine comprising the same.

The invention provides allicin-rich plant vesicles and a preparation method and application thereof.The preparation method includes the steps that after garlic juice is prepared and continuous centrifugal impurity removal is conducted, allicin is enriched through PEG800, small nano vesicles, large micro vesicles and allicin polymers are sequentially and coarsely extracted from garlic, lipophilic components are extracted, thin film evaporation is conducted to form thin films, hydration is conducted to form reconstructed vesicles, and the allicin-rich plant vesicles are obtained. The allicin can be stably and abundantly wrapped in the recombinant vesicles to form ASL-EVLPs, high-content allicin can be effectively entrapped, the stability of the allicin is remarkably improved, and the irritation of the allicin is reduced. The allicin-rich plant vesicles prepared by the method provided by the invention delay the drug resistance of bacteria and effectively resist infection by adopting a drug preparation mode, can realize broad-spectrum antibiosis and delay the drug resistance of bacteria, have an inhibition effect on part of gram-positive bacteria, gram-negative bacteria and fungi, and can be used for preparing antibiosis-related drugs.

The present invention relates to compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by β-glucan. The monocytes are preferably incubated with β-glucan and then treated to extract particles, such as microvesicles and exosomes, from the treated monocytes to produce the cytotoxic composition. Preferably, the cytotoxic composition contains at least 50% β-glucan-activated exosomes having a size of 150 nm or less. Zymosan is a preferred β-glucan. The cytotoxic composition has an apoptotic effect. When a subject with cancer is treated according to the preferred embodiment, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and the cytokine response is synergistic.

Embodiments of the disclosure include treatments of subconcussive and / or concussive brain damage by administering fibroblasts and / or fibroblasts cultured with one or more types of immunocytes. In one specific embodiment fibroblasts are cultured with monocytes in the presence of patient-specific T cells, and subsequently the T cells are re-administered into the patient. In one particular embodiment, products derived from fibroblast-immunocyte mixtures are comprised of cellular lysate, apoptotic bodies, exosomes, and / or other microvesicles. In one embodiment, the fibroblast cells and / or products derived from the fibroblast cells are administered subsequent to one or multiple head injuries. In other embodiments, products are administered in combination with neurorestorative and / or neuroprotective interventions.

A method of manufacturing a suspension of gas-filled microvesicles by reconstituting a freeze-dried product and a suspension obtained according to said method, where the freeze-dried product has been subjected to a thermal treatment.

The application relates to the technical field of stem cell engineering and regenerative medicine, and specifically discloses a stem cell treatment method for treating type 2 diabetes. The method comprises the following steps: S1, extracting placenta-derived mesenchymal stem cells; S2, performing multi-gene modification on the mesenchymal stem cells to obtain gene-modified mesenchymal stem cells; S3, pretreating the gene-modified mesenchymal stem cells with a culture medium; S4, extracting microvesicles from the mesenchymal stem cells; S5, mixing the microvesicles, baicalin, L-arginine and vitamin D in a buffer to form a composite preparation; S6, introducing the composite preparation into a patient's body through abdominal cavity intervention; and S7, performing synergistic treatment by combining oral administration of an SGLT2 inhibitor after infusion, and regularly monitoring islet function indexes. The stem cell treatment method can be used for treating type 2 diabetes, and has the advantages of being targeted to improve the islet microenvironment, promoting the recovery of beta cell function and being durable in action.

A method for constructing a saRNA microvesicle delivery system includes the following steps: (1) designing a saRNA expression vector 1 and a membrane protein expression vector 2; and (2) co-transfecting the expression vector 1 and the expression vector 2 into a host cell; and (3) culturing the host cell, and isolating microvesicles containing a saRNA, the saRNA containing a target gene sequence, a replicon in the saRNA expression vector being an alphavirus replicon, and the microvesicles not containing capsid protein. The system can efficiently deliver the saRNA to cells or in vivo to realize the expression of a target protein. On this basis, different elements in the delivery system can be further transformed to develop a high-efficiency low-immunogenicity modular platform aiming at different diseases and different targets. The delivery system may supplement the toolbox of existing viral and lipid nanoparticle delivery vectors and has good application prospects.

The invention discloses citrus-derived microvesicles, a preparation method thereof and application of the citrus-derived microvesicles in intestinal inflammation treatment. Citrus juice is subjected to gradient ultracentrifugation, and a crude extract is obtained; and carrying out tangential flow membrane separation or polymer and ultrasonic-assisted separation or sucrose density gradient ultracentrifugation on the obtained crude extract to obtain the citrus-derived microvesicles CDENs. According to the invention, the CDENs are separated from the citrus juice, and the high-content PC endows the CDENs with the capacity of targeting colonic macrophages; after oral administration, the CDENs tolerate the gastrointestinal tract digestion environment, and after reaching the intestinal inflammation part, the CDENs are retained due to intestinal barrier injury caused by inflammation and are internalized by macrophages; through PC-mediated signal channel regulation and control, the CDENs realizes a multi-target synergistic effect of macrophage phenotype polarization, inflammation channel inhibition, oxidative stress relief, intestinal barrier repair and intestinal flora regulation, and finally, the intestinal inflammation condition is relieved.

The invention relates to new calibrated-size gas-filled microvesicles bearing an overall negative charge, to their method of manufacturing and to their use. Said gas-filled microvesicles have a geometric standard deviation (GSD) value of at least 1.20 or lower and a stabilizing envelope comprising a phospholipid selected from phosphatidic acid, phosphatidylserine or a mixture thereof and a pegylated phospholipid.

The invention relates to the technical field of cell carrier microvesicle transfection, and discloses an electric pulse field accurate control system for physical transfection of cell carrier microvesicles. Comprises: a parameter determination module configured to determine a short-time high-voltage electric pulse application scheme according to physicochemical property parameters of cell carrier microvesicles; the dynamic adjustment module is configured to mix the cells and exogenous contaminants, transfer the cells and the exogenous contaminants to the electrode cup, and dynamically adjust the applied voltage, capacitance and pulse frequency based on the phenomenon of uneven voltage distribution caused by surface tension of liquid in the electrode cup; and the tracking processing module is configured to continuously track electrochemical reaction characteristics in a transfection process, process toxic substances and bubbles generated by the electrochemical reaction, guarantee an electrotransfection effect of cells in a stable field intensity current region, realize accurate control of an electric pulse field and improve the transfection efficiency of the cell carrier microvesicles. The invention provides a breakthrough solution for efficient transfection of the microvesicles.

The invention relates to the use of a probiotic composition comprising a lactic acid producing bacterial strain, a conditioned medium or microvesicles from the lactic acid producing bacterial strain in treatment or prevention of hyposecretinemia. The lactic acid producing bacterial strain, the conditioned medium and / or the microvesicles is or are capable of inducing release, and optionally production, of secretin locally in a gastrointestinal tract of a subject suffering from hyposecretinemia or having a risk of suffering from hyposecretinemia. The invention also relates to screening of lactic acid producing bacterial strains suitable in treatment or prevention of hyposecretinemia. Secretin

The invention relates to a double-layer detachable microneedle which comprises a soluble microneedle tip and a detachable hydrogel substrate layer, and the microneedle tip layer comprises at least one of drugs, extracellular vesicles, macromolecular substances and combinations of the drugs, the extracellular vesicles and the macromolecular substances. The extracellular vesicles are one or a combination of a plurality of exosomes, microvesicles, apoptotic bodies, autophagy-related extracellular vesicles, matrix vesicles and stress-related extracellular vesicles, and the macromolecular substances are one or a combination of a plurality of polypeptides, proteins, antigens, enzymes and antibodies. According to the double-layer detachable microneedle, early-stage antibiosis and pH adjustment can be achieved, infection is reduced, and inflammation is inhibited; macrophages are induced to be polarized from M1 to M2, and inflammation is promoted to be transited to a proliferation stage; needle tip loading is continuously released, and angiogenesis, cell proliferation and tissue regeneration are enhanced; the double-layer structure can sequentially respond to different stage requirements of the wound, and the healing efficiency of the diabetic wound is remarkably improved.

The present invention relates to a method for extracting microvesicles from a biological sample, the method comprising the steps of: adding a polyvalent cationic material to the biological sample to form an aggregate in which the microvesicles and the polyvalent cationic material are aggregated by electrical force; capturing the aggregate by a capture filter while the biological sample including the aggregate passes through the capture filter; and extracting the microvesicles by allowing an elution solution to pass through the capture filter with the aggregate captured therein to isolate the microvesicles from the aggregate. Accordingly, microvesicles may be extracted using a polyvalent cationic material, without a centrifugation process.